All In Biotech

Drug Trial Radar · NCT05600777

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2)

Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 997 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

997

Actual

Start

Dec 5, 2022

Primary completion

Jun 10, 2026

Study completion Mar 17, 2027

Sponsor

Sponsor type
Industry
First posted
Oct 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Conditions

  • Cough
  • Refractory Chronic Cough

Interventions

  • BLU-5937Drug

    Oral administration of BLU-5937 Tablets

  • PlaceboDrug

    Oral administration of matching placebo for BLU-5937 Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 24-Hour Cough FrequencyTime frame: Week 24
  2. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) up to Week 24Time frame: Up to Week 24
  3. Number of Participants with Adverse Events of Medical Interest (AEMIs) up to Week 24Time frame: Up to Week 24
  4. Number of Participants with Study Treatment Discontinuation due to AEs and SAEs up to Week 24Time frame: Up to Week 24
  5. Number of Participants with AEs and SAEs Leading to Study Withdrawal up to Week 24Time frame: Up to Week 24
  6. Change from Baseline in Vital Signs: Systolic and Diastolic Blood Pressure (millimeters of mercury [mm Hg]) at Week 24Time frame: Baseline, Week 24
  7. Change from Baseline in Vital Sign: Pulse (beats per minute) at Week 24Time frame: Baseline, Week 24
  8. Change from Baseline in Vital Sign: Respiratory Rate (breaths per minute) at Week 24Time frame: Baseline, Week 24
  9. Change from Baseline in Vital Sign: Body Temperature (degrees Celsius) at Week 24Time frame: Baseline, Week 24
  10. Change from Baseline in Vital Sign: Weight (kilograms [kg]) at Week 24Time frame: Baseline, Week 24
  11. Change from Baseline in Male Reproductive Hormone: Total Testosterone (nanomoles per liter [nmol/L]) at Week 24Time frame: Baseline, Week 24
  12. Change from Baseline in Male Reproductive Hormones: Follicle-Stimulating Hormone [FSH] and Luteinizing Hormone [LH] (international units per liter [IU/L]) at Week 24Time frame: Baseline, Week 24
  13. Change from Baseline in Male Reproductive Hormone: Inhibin B (nanograms per liter [ng/L]) at Week 24Time frame: Baseline, Week 24
  14. Change from Baseline in Hematology Parameter: Red Blood Cell (RBC) Count (10^12 cells per liter) at Week 24Time frame: Baseline, Week 24
  15. Change from Baseline in Hematology Parameters: Hemoglobin and Mean Corpuscular Hemoglobin Concentration (MCHC) (grams per liter [g/L]) at Week 24Time frame: Baseline, Week 24
  16. Change from Baseline in Hematology Parameter: Hematocrit (percentage) at Week 24Time frame: Baseline, Week 24
  17. Change from Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV) (femtoliters [fL]) at Week 24Time frame: Baseline, Week 24
  18. Change from Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH) (picograms per cell [pg/cell]) at Week 24Time frame: Baseline, Week 24
  19. Change from Baseline in Hematology Parameter: Red Cell Distribution Width (RDW) (percentage) at Week 24Time frame: Baseline, Week 24
  20. Change from Baseline in Hematology Parameters: White Blood Cell (WBC) Count (neutrophils, lymphocytes, monocytes, eosinophils, and basophils) and Platelet Count (10^9 cells per liter) at Week 24Time frame: Baseline, Week 24
  21. Change from Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma-Glutamyl Transferase (GGT) (units per liter [U/L]) at Week 24Time frame: Baseline, Week 24
  22. Change from Baseline in Clinical Chemistry Parameters: Alkaline Phosphatase (ALP) and Creatine Kinase (CK) (international units per liter [IU/L]) at Week 24Time frame: Baseline, Week 24
  23. Change from Baseline in Clinical Chemistry Parameters: Total Bilirubin, Direct and Indirect Bilirubin, and Creatinine (micromoles per liter) at Week 24Time frame: Baseline, Week 24
  24. Change from Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Chloride, Calcium, Magnesium, Bicarbonate, Glucose, and Blood Urea Nitrogen (BUN) (millimoles per liter [mmol/L]) at Week 24Time frame: Baseline, Week 24
  25. Change from Baseline in Clinical Chemistry Parameters: Protein and Albumin (grams per liter [g/L]) at Week 24Time frame: Baseline, Week 24
  26. Change from Baseline in Clinical Chemistry Parameter: Estimated Glomerular Filtration Rate (eGFR) (milliliters per minute per 1.73 meters squared [mL/min/1.73 m^2]) at Week 24Time frame: Baseline, Week 24
  27. Change from Baseline in Clinical Chemistry Parameters: Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) (seconds) at Week 24Time frame: Baseline, Week 24
  28. Change from Baseline in Electrocardiogram (ECG) Value: Heart Rate (beats per minute) at Week 24Time frame: Baseline, Week 24
  29. Change from Baseline in ECG Value: PR Interval, QT Interval, RR Interval, QRS Interval, and Corrected QT Interval Using Fridericia's Formula (QTcF) (milliseconds) at Week 24Time frame: Baseline, Week 24

Locations

242 sites in 13 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Foley, Alabama

  • GSK Investigational Site

    Litchfield Park, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Paramount, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Jose, California

  • GSK Investigational Site

    Aurora, Colorado

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Wheat Ridge, Colorado

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Daytona Beach, Florida

  • GSK Investigational Site

    Fort Lauderdale, Florida

  • GSK Investigational Site

    Jacksonville, Florida

  • GSK Investigational Site

    Leesburg, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Santa Rosa Beach, Florida

  • GSK Investigational Site

    Sarasota, Florida

  • GSK Investigational Site

    Sweetwater, Florida

  • GSK Investigational Site

    Cumming, Georgia

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    River Forest, Illinois

  • GSK Investigational Site

    West Des Moines, Iowa

  • GSK Investigational Site

    Lexington, Kentucky

  • GSK Investigational Site

    Chevy Chase, Maryland

  • GSK Investigational Site

    Methuen, Massachusetts

  • GSK Investigational Site

    North Dartmouth, Massachusetts

  • GSK Investigational Site

    Ypsilanti, Michigan

  • GSK Investigational Site

    Edina, Minnesota

  • GSK Investigational Site

    Woodbury, Minnesota

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Missoula, Montana

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Gastonia, North Carolina

Showing 40 of 242 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.